Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
May 14, 2020 08:00 ET
|
Constellation Pharmaceuticals , Inc.
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow...
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
May 06, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
May 05, 2020 14:06 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
April 28, 2020 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors
April 06, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 10, 2020 16:12 ET
|
Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
March 06, 2020 13:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2020 12:33 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 13, 2019 16:05 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 10, 2019 21:05 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...